• Susanne Saussele, Wilhelm Haverkamp, Fabian Lang, Steffen Koschmieder, Alexander Kiani, Kathleen Jentsch-Ullrich, Frank Stegelmann, Heike Pfeifer, Paul La Rosée, Nicola Goekbuget, Christina Rieger, Cornelius F Waller, Georg-Nikolaus Franke, le Coutre Philipp P Department of Medicine, Hematology and Oncology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universitä, Rudolf Kirchmair, and Christian Junghanss.
• Department of Haematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany, susanne.saussele@medma.uni-heidelberg.de.
• Acta Haematol. 2020 Jan 1; 143 (3): 217-231.

AbstractTreatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia (Ph+ ALL) has been revolutionized with the advent of tyrosine kinase inhibitors (TKIs). Most patients with CML achieve long-term survival similar to individuals without CML due to treatment with TKIs not only in frontline but also in further lines of therapy. The third-generation TKI ponatinib has demonstrated efficacy in patients with refractory CML and Ph+ ALL. Ponatinib is currently the most potent TKI in this setting demonstrating activity against T315I mutant clones. However, ponatinib's safety data revealed a dose-dependent, increased risk of serious cardiovascular (CV) events. Guidance is needed to evaluate the benefit-risk profile of TKIs, such as ponatinib, and safety measures to prevent treatment-associated CV events. An expert panel of German hematologists and cardiologists summarize current evidence regarding ponatinib's efficacy and CV safety profile. We propose CV management strategies for patients who are candidates for ponatinib.© 2019 The Author(s) Published by S. Karger AG, Basel.

56 keywords...

hide…